tradingkey.logo

LivaNova PLC

LIVN
查看詳細走勢圖
62.820USD
+0.740+1.19%
收盤 12/19, 16:00美東報價延遲15分鐘
3.43B總市值
虧損本益比TTM

LivaNova PLC

62.820
+0.740+1.19%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.19%

5天

+0.11%

1月

+16.53%

6月

+39.07%

今年開始到現在

+35.65%

1年

+32.28%

查看詳細走勢圖

TradingKey LivaNova PLC股票評分

單位: USD 更新時間: 2025-12-19

操作建議

LivaNova PLC當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名2/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價67.73。中期看,股價處於上升通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

LivaNova PLC評分

相關信息

行業排名
2 / 208
全市場排名
29 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 10 分析師
買入
評級
67.732
目標均價
+8.08%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

LivaNova PLC亮點

亮點風險
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
業績高增長
公司營業收入穩步增長,連續3年增長22.67%
估值合理
公司最新PE估值-15.77,處於3年歷史合理位
機構減倉
最新機構持股56.86M股,環比減少13.00%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉12.03K股

LivaNova PLC新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

LivaNova PLC簡介

LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
公司代碼LIVN
公司LivaNova PLC
CEOMakatsaria (Vladimir A)
網址https://www.livanova.com/

常見問題

LivaNova PLC(LIVN)的當前股價是多少?

LivaNova PLC(LIVN)的當前股價是 62.820。

LivaNova PLC 的股票代碼是什麼?

LivaNova PLC的股票代碼是LIVN。

LivaNova PLC股票的52週最高點是多少?

LivaNova PLC股票的52週最高點是65.574。

LivaNova PLC股票的52週最低點是多少?

LivaNova PLC股票的52週最低點是32.480。

LivaNova PLC的市值是多少?

LivaNova PLC的市值是3.43B。

LivaNova PLC的淨利潤是多少?

LivaNova PLC的淨利潤為63.23M。

現在LivaNova PLC(LIVN)的股票是買入、持有還是賣出?

根據分析師評級,LivaNova PLC(LIVN)的總體評級為買入,目標價格為67.732。

LivaNova PLC(LIVN)股票的每股收益(EPS TTM)是多少

LivaNova PLC(LIVN)股票的每股收益(EPS TTM)是-3.983。
KeyAI